Q&A with Gibraltar Laboratories - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Gibraltar Laboratories
The president of Gibraltar Laboratories, Daniel Prince, discusses industry trends and challenges.

Pharmaceutical Technology
Volume 10, Issue 34, pp. 85

PharmTech:



What is the biggest industry challenge you're now facing?

Prince

The biggest challenge that our industry faces is uncertainty about the economy. Because labor is less expensive overseas, manufacturing and administrative jobs are being lost in America to foreign competitors. Furthermore, because businesses are being overtaxed and overregulated, our home-based companies are at a competitive disadvantage.

PharmTech:

How do you stay abreast of new developments in the industry?

Prince

I stay current by doing a lot of reading and getting out to meet my customers and colleagues. I am also inviting other successful laboratories to share best practices.

One of our best practices is offering our own legal documents such as confidentiality agreements and audit procedural agreements. This initiative allows us to schedule audits quickly because legal review, if any, is not as necessary. Having 1000 audits per year by 1000 customers, all of whom have their own confidentiality agreements, is a burden and mostly wastes valuable time and legal resources.

PharmTech:

Do you see a new industry trend emerging?

Prince

We are committed to rapid testing techniques. New alternatives to some classical microbiological tests are available, and they can save one to four days. We are educating our customers about the advantages and disadvantages of these new microbiology rapid techniques.

We have invested in fluorescent and kinetic instruments, but we have not decided yet what our next steps will be. We would be interested in a rapid sterility test. The risks of rapid technologies are that they are expensive and require reliance on a sole source for supplies and repairs. The advantages of existing US Pharmacopeia microbiology methods are that they are affordable and can be performed by laboratories all over the world, including in developing countries.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here